Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BYL719 and T-DM1 in HER2+ Metastatic Breast Cancer
NCT02038010Phase 1Completed
- Sponsor
- Northwestern University
- Start
- May 2014
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of alpelisib in breast cancer, sponsored by Northwestern University. Primary endpoints: Dose Limiting Toxicity and Maximum Tolerated Dose. Started May 2014; status: completed.
02
Drugs
alpelisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02038010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02038010.